---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116491"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:35:04.467659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q3 gross royalties $65.6M, income before taxes surges to $286.4M on TRC sale gain

## Summary
- Gross royalty revenues of $65.6M (flat YoY) from RELVAR/BREO ($55.7M) and ANORO ($9.9M).
- Income before taxes rose to $286.4M from $123.2M, primarily due to gain from sale of 15% TRC interest to Royalty Pharma for $282M.
- Completed acquisitions: Entasis for $42.4M and La Jolla for net cash $150.5M, expanding hospital/infectious disease portfolio.
- Board authorized new $100M share repurchase program; no termination date, management discretion.
- GSK reported RELVAR/BREO net sales $371.1M (+3% YoY) and ANORO $153.0M (-15% YoY), reflecting currency and pricing headwinds.

## SEC filing metadata
- accession: 0001104659-22-116491
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465922116491/0001104659-22-116491-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465922116491/tm2230075d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116491
- JSON: https://secwatch.observer/filing/0001104659-22-116491.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116491.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.